Bruce Brown - Medpace Holdings Independent Director
| MEDP Stock | USD 395.93 6.16 1.58% |
Director
Mr. Bruce Brown is an Independent Director of the company. Mr. Brown has served as a member of our Board since October 27, 2016. Mr. Brown currently serves as a member of the board of directors, Chairman of the Personnel Committee and a member of the Corporationrationrate Governance and Nomination Committee of Nokia Corporationrationration. He was a member of Nokia Corporationrationrations board of directors, its Corporationrationrate Governance and Nomination Committee and its Personnel Committee since 2012, and has served as Chairman of the Personnel Committee since May 2014. Mr. Brown also currently serves as a member of the board of directors and the Audit Committee and Nominating and Corporationrationrate Governance Committee of P. H. Glatfelter Company. He was a member of P. H. Glatfelter Companys board of directors since 2014, and was a member of its Audit Committee and its Nominating and Corporationrationrate Governance Committee since 2014. Mr. Brown retired from The Procter Gamble Company in 2014, where he served as Chief Technology Officer from 2008 to 2014 and in various executive and managerial positions in the Baby Care, Feminine Care and Beauty Care units from 1980 to 2008, and he has lived and worked in the U.S., Germany and Japan. Mr. Brown was a member of the board of directors of the Agency for Science, Technology Research in Singapore from 2011 to 2018. He was a member of the board of trustees of Xavier University from 2010 to May 2016. Mr. Brown received his BS in Chemical Engineering from the Polytechnic Institute of New York University and his MBA from Xavier University. Mr. Brown was chosen as a director because of his significant experience as a member of the boards of directors and various committees of the boards of directors of public companies and as an executive of a public company. since 2016.
| Age | 59 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 513 579 9911 |
| Web | https://www.medpace.com |
Medpace Holdings Management Efficiency
The company has return on total asset (ROA) of 0.1389 % which means that it generated a profit of $0.1389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6135 %, meaning that it created $0.6135 on every $100 dollars invested by stockholders. Medpace Holdings' management efficiency ratios could be used to measure how well Medpace Holdings manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Xiaoying Mai | Twist Bioscience Corp | 30 | |
| Joan Garahy | ICON PLC | 54 | |
| Dermot Kelleher | ICON PLC | 58 | |
| Gary Gilliland | Laboratory of | 63 | |
| Edward Conard | Waters | 63 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Michael Berendt | Waters | 71 | |
| Paul Conley | Twist Bioscience Corp | 49 | |
| Francis Contino | Mettler Toledo International | 70 | |
| Robert Chess | Twist Bioscience Corp | 61 | |
| Sophie Vandebroek | IDEXX Laboratories | 56 | |
| Garheng Kong | Laboratory of | 45 | |
| Ronan Lambe | ICON PLC | 74 | |
| Charles Fischer | Neogen | 73 | |
| Caspar Tudor | Waters | N/A | |
| Gary Hendrickson | Waters | 64 | |
| Sanders Williams | Laboratory of | 69 | |
| Bruce Claflin | IDEXX Laboratories | 66 | |
| Keith Crandell | Twist Bioscience Corp | 58 | |
| William Boehm | Neogen | 70 | |
| Hugh Brady | ICON PLC | 57 | |
Management Performance
| Return On Equity | 0.61 | ||||
| Return On Asset | 0.14 |
Medpace Holdings Leadership Team
Elected by the shareholders, the Medpace Holdings' board of directors comprises two types of representatives: Medpace Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medpace. The board's role is to monitor Medpace Holdings' management team and ensure that shareholders' interests are well served. Medpace Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medpace Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan Burwig, Senior Vice President - Operations | ||
| Cornelius McCarthy, Director | ||
| Anastasya Molodykh, Director | ||
| Kevin Brady, CFO Treasurer | ||
| Jesse Geiger, CFO, COO - Laboratory Operations | ||
| Stephen JD, General Officer | ||
| Stephen Ewald, General Counsel, Corporate Secretary | ||
| Bruce Brown, Independent Director | ||
| Matthew Norton, Independent Director | ||
| John MBA, Senior Unit | ||
| MA BSN, Executive Operations | ||
| Ashley Keating, Director | ||
| John Richardson, Director | ||
| Fred Davenport, Director | ||
| August Troendle, Chairman of the Board and Presidentident, CEO | ||
| Alexander Leslie, Independent Director | ||
| Brandon Ebken, Chief Officer | ||
| August MD, Chairman CEO | ||
| Todd Meyers, Vice Marketing | ||
| Reinilde MD, Chief Department | ||
| Weimin MS, VP Biometrics | ||
| Supraj Rajagopalan, Independent Director | ||
| Penelope Bucknell, Vice President - Human Resources | ||
| Daniel OLeary, VP Department | ||
| Brian Carley, Independent Director | ||
| Robert Kraft, Independent Director | ||
| CPA BBA, President | ||
| Lauren Morris, Associate Relations |
Medpace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medpace Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.61 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 11.99 B | ||||
| Shares Outstanding | 30.98 M | ||||
| Shares Owned By Insiders | 18.16 % | ||||
| Shares Owned By Institutions | 81.68 % | ||||
| Number Of Shares Shorted | 984.45 K | ||||
| Price To Earning | 49.07 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medpace Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Medpace Stock, please use our How to Invest in Medpace Holdings guide.Note that the Medpace Holdings information on this page should be used as a complementary analysis to other Medpace Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Medpace Stock analysis
When running Medpace Holdings' price analysis, check to measure Medpace Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medpace Holdings is operating at the current time. Most of Medpace Holdings' value examination focuses on studying past and present price action to predict the probability of Medpace Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medpace Holdings' price. Additionally, you may evaluate how the addition of Medpace Holdings to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Medpace Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medpace Holdings. If investors know Medpace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medpace Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Medpace Holdings is measured differently than its book value, which is the value of Medpace that is recorded on the company's balance sheet. Investors also form their own opinion of Medpace Holdings' value that differs from its market value or its book value, called intrinsic value, which is Medpace Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medpace Holdings' market value can be influenced by many factors that don't directly affect Medpace Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medpace Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Medpace Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medpace Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.